INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with a 5-year survival rate of less than 5% (1) . PDAC tumors are thought to originate from mature acinar cells that transdifferentiate into ductal-like cells, a process known as acinar to ductal metaplasia (ADM) (2, 3) . ADM can be induced by pancreatitis or oncogenic mutations. Only under sustained oncogenic insult will pancreatic cells that have undergone ADM progress through a series of histopathological stages called pancreatic intraepithelial neoplasias (PanINs) to invasive PDAC.
Nearly all PDAC and a high percentage of early PanIN lesions have KRAS mutations (4) . The human ADM-to-PanIN-to-PDAC progression has been recapitulated using genetically engineered mouse models (GEMMs) in which endogenous expression of oncogenic Kras is induced in the developing pancreas, either alone or in conjunction with the inactivation of other commonly mutated tumor suppressor genes, such as p16, Trp53, or Smad4 (5-8). When oncogenic Kras is activated alone, ADM and early PanINs readily develop, but progression into late-stage PanINs and eventually PDAC is delayed (8) . This process is substantially accelerated by mutation of p16, Trp53, or Smad4, suggesting that the proteins encoded by these genes inhibit the proliferative signals mediated by mutant Kras (5) (6) (7) .
Despite recent progress, oncogenic KRAS itself remains an extremely challenging therapeutic target (9, 10) . Thus, much effort is devoted to identifying critical downstream effectors of oncogenic KRAS. Because the development and progression of PDAC are strongly influenced by the microenvironment, GEMMs represent the most physiologically relevant models. In the past few years, the aforementioned GEMMs have been crossed with mice harboring various loss-of-function mutant alleles, leading to the identification of genes required for the initiation (EGFR, ADM17, PDK1, Gli1, and Sox9) or progression (Rac1, STAT3, IL-6, NEMO, and IKK2) of PDAC in the context of Kras mutation, either alone or concurrent with p16 deletion (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . However, introduction of Trp53 mutations into these models (which mimic the TP53 mutations found in the majority of human PDAC) mitigated the requirement for many of these genes during PDAC initiation and progression (11, 17, 19, 20) . In accord with these findings in GEMMs, clinical trials of inhibitors targeting the epidermal growth factor receptor (EGFR), the RAF-mitogen-activated protein kinase (MAPK) pathway, phosphoinositide 3-kinase, or the Hedgehog pathway have been largely unsuccessful (23) . Thus, there remains an urgent need to discover the "Achilles' heel" that governs PDAC development in the presence of KRAS:TP53 mutations.
The Yes-associated protein (YAP), encoded by YAP1, referred to herein simply as Yap, is a bona fide oncoprotein, and its abundance and activity are frequently increased in many types of cancers (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . YAP is a transcriptional coactivator that partners with the TEAD family of transcription factors to promote the expression of pro-proliferative and antiapoptotic genes (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) . Extensive genetic studies that focused primarily on organ size control in Drosophila and mice identified that the Hippo pathway is the canonical regulator of YAP activity (39, (47) (48) (49) (50) . The Hippo pathway is composed of a kinase cascade in which the MST1 and MST2 (MST1/2) Hippo kinases are facilitated by scaffold protein WW45 to phosphorylate the LATS1 and LATS2 (LATS1/2) kinases and their adaptor protein, MOB1 (43, 45, (51) (52) (53) . Phosphorylated LATS1/2 kinases in turn phosphorylate YAP, inactivating YAP by causing it to be retained in the cytoplasm and degraded (54, 55) . A host of factors [including cell density, extracellular matrix stiffness, G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptors, protease-activated receptors, EGFR, and leukemia inhibitory factor receptor] influence YAP activity by modulating the Hippo pathway (56) (57) (58) (59) (60) . Additionally, accumulating evidence indicates that YAP activity can be regulated by noncanonical, Hippoindependent mechanisms (61) (62) (63) (64) (65) (66) (67) .
GEMMs developed in recent years have revealed critical functions of YAP and the Hippo pathway in the maintenance of tissue homeostasis, the organ size checkpoint, and tumorigenesis. Tissue-specific overexpression of Yap or inactivation of Hippo signaling through the homozygous deletion of Mst1/2 or genes encoding other components of the Hippo pathway resulted in enlargement of the liver, heart, and intestine, as well as tumorigenesis in the liver (47, 49, 68, 69) . In contrast, deletion of Mst1/2 or ectopic expression of Yap in the developing mouse pancreas induces ADM and impairs differentiation of exocrine and endocrine compartments without increasing the size of the pancreas or inducing pancreatic tumor development (70, 71) . These studies demonstrate that activation of YAP alone is insufficient to induce PDAC, but have not determined whether YAP is necessary for PDAC development. Here, we examined YAP abundance in primary human PDAC, its role in mutant KRAS-and KRAS:TP53-mediated PDAC initiation and progression, and the molecular mechanisms underlying oncogenic RAS-YAP crosstalk.
RESULTS

YAP is expressed in normal and neoplastic pancreatic ductal cells
YAP abundance is increased in human PDAC (72, 73) . Through a metaanalysis of published human PDAC microarray data sets (74-77), we confirmed that overall YAP mRNA abundance was significantly increased in human PDAC when compared to normal pancreatic tissues ( fig. S1A ). For reference, the genotypes of all GEMMs used in this study are listed in table S1. The Kras G12D/+ :p48-Cre (KC) and Kras G12D/+ :Trp53 R172H/+ :p48-Cre (KPC) GEMMs in which p48-Cre (also known as Ptf1a-Cre) induces the expression of mutant Kras alone or together with mutant Trp53 in murine pancreatic epithelium fully recapitulate the pathogenesis of human PDAC and are generally regarded as two of the best GEMMs for human PDAC (23) . By Western blot analysis, we found that Yap protein abundance was also markedly greater in pancreatic tissue from KPC mice that had developed PDAC compared with that from wild-type mice (fig. S1B).
To explore this association further, we performed immunohistochemistry (IHC) analysis for YAP on two human tissue microarrays (TMAs) containing 31 normal pancreata, 64 chronic pancreatitis or tumor adjacent tissues, and 140 PDAC tumor cores, as well as pancreatic sections from multiple wild-type, KC, and KPC mice (figs. S1, C to I, and S2A). Consistent with previous reports (72, 73) , we found that YAP abundance was restricted to ductal and terminal-duct centroacinar cells in normal human and mouse pancreas tissue (figs. S1D and S2A and table S2). Variable amounts of cytoplasmic or nuclear YAP were also detected in a significant fraction of neoplastic ductal epithelial cells and stromal cells in almost all of the PDAC tumors and adjacent tissues containing benign lesions and chronic pancreatitis (fig. S1, C and E to G, and table S2). Similar patterns of Yap staining were observed in pancreata from KC and KPC mice that had early PanINs or fully established PDAC (fig. S1, H and I). Although a fraction of human PDAC tumors exhibited intense staining for YAP (particularly in late-stage tumors), the majority of human PDAC tumors appeared to have an abundance of YAP within individual tumor cells that was comparable to that in normal centroacinar and ductal cells ( fig. S1 , C to G, and table S2). Thus, the overall increase in YAP abundance in PDAC measured by microarray and Western blot analyses (fig. S1, A and B) likely resulted from the expansion of neoplastic ductal and stromal cell populations, rather than from a net increase in YAP transcript and abundance in individual PDAC cells.
Yap is dispensable for normal pancreatic development and glucose metabolism
Because YAP is present in normal centroacinar and ductal cells, we investigated whether the deletion of Yap might affect the normal development or function of the pancreas by generating Yap flox/flox :p48-Cre (YC) mice. YC mice were born at the Mendelian ratio and had normal weight, physical appearance, and life expectancy. IHC analysis confirmed the complete loss of Yap expression in the pancreatic epithelium of YC mice ( fig. S2A ). Despite the absence of Yap, YC pancreata were indistinguishable from wild-type pancreata in overall histology by hematoxylin and eosin (H&E), staining patterns for major pancreatic cell lineage markers [including amylase (in acinar cells), cytokeratin 19 (CK19; in ductal cells), insulin (in b cells within the islets), and glucagon (in a cells within the islets)], or organization of ductal networks ( fig. S2, B and C) . A glucose tolerance test also revealed no apparent difference between YC and wild-type mice in their ability to modulate blood glucose levels ( fig. S2D ). Collectively, these data suggest that YAP deletion from the pancreatic epithelium is inconsequential to normal pancreatic development, homeostasis, and glucose metabolism. fig. S3 ). These ADM and early PanINs progressed through late-stage PanINs and eventually to invasive PDAC by 2 to 4 months in KPC mice, or from 6 months to 2 years in KC mice (Fig. 1, A to C, and fig. S3 ). In contrast, all the KYC and KPYC mice with homozygous Yap deletions completely lacked any late-stage PanINs or PDAC when analyzed at all the tested time points, even at the age of 12 months (for KC mice) or 10 months (for KPC mice) (Fig. 1, A to C, and fig. S3 ).
Inactivation of Yap blocks PDAC development in
Although ADM and some PanIN-1 lesions that were CK19-positive and Yap-negative (CK19 + :Yap − ) still developed in KYC and KPYC pancreata (Fig. 1, A and B, and fig. S3, A and B) , nearly all pancreatic tissue areas in these mice were histologically normal across all age groups (Fig. 1, A and D,  and fig. S3A ). In contrast, from the age of 9 weeks, the number of lesions at various stages of progression increased in the pancreata from KC and KPC mice (Fig. 1, A and D, and fig. S3A ).
Whereas nearly all KPC and half of KC mice died from PDAC by 6 months or 1.5 years of age, respectively, not a single KPYC or KYC mouse in our experimental cohort succumbed to PDAC within the same periods (Fig. 1E) . These results clearly demonstrate that YAP is essential in mutant KRAS-and KRAS:TP53-mediated PDAC development. To understand how Yap deletion blocked the progression of PanINs to PDAC, we stained pancreatic sections from KC, KYC, KPC, and KPYC mice with markers for proliferation (Ki-67), apoptosis (cleaved caspase-3), and senescence (SA-b-gal). Although there were no general differences in cleaved caspase-3 or SA-b-gal staining in the pancreata from KPC and KPYC mice ( fig. S6 , A to C), pancreata from KYC and KPYC mice exhibited a markedly reduced number of Ki-67-positive cells compared with those from KC and KPC mice (Fig. 3, A Collectively, our data demonstrate that YAP is essential in maintaining persistent cell proliferation required for PanIN progression into PDAC in KRAS and KRAS: TP53 mutant pancreata.
Yap drives the expression of multiple secretory factors in KRAS and KRAS:TP53 mutant pancreatic ductal cells
We hypothesized that as a transcriptional regulator, YAP likely controls the proliferation of KRAS and KRAS:TP53 mutant pancreatic ductal cells by regulating the expression of KRAS-induced pro-proliferative genes. We performed an unbiased screen of ( Fig. 4 , A to C, and fig. S8, C to F). All six genes are implicated in PDAC progression; five of these encode secretory proteins and the sixth encodes COX2, which is responsible for the synthesis of the lipid prostaglandin E 2 (PGE 2 ), which promotes inflammation, among other activities (12) (13) (14) (80) (81) (82) (83) (84) . Consistent with the notion that YAP sustains the proliferation of KRAS-mutant pancreatic ductal cells by promoting the expression of pro-proliferative secretory factors, we found that conditioned medium from Yap-reconstituted KPY cells overcame the proliferative defect exhibited by Yap-deficient KPY cells (Fig. 4D) . Moreover, combined treatment with recombinant MMP7, Il-6, Il-1a, and PGE 2 stimulated the proliferation of Yap-deficient KPY cells, but not Yap-reconstituted KPY cells (Fig. 4E ), whereas treatment with individual proteins or various combinations had variable and generally less pronounced effects on the proliferation of either Yap + or Yap − pancreatic ductal cells. These results suggest that lack of expression of these secreted factors underlies the proliferative defect of Yap null KPY cells and also highlight the complex interactions among these factors in the context of YAP.
COX2 and MMP7 are two novel YAP target genes that contribute to sustaining the proliferation of KRAS:TP53 mutant pancreatic ductal cells Whereas CTGF and CYR61 are well-established YAP target genes in multiple cell types (85) (86) (87) , to our knowledge no previous reports link the abundance of COX2, MMP7, IL-6, and IL-1a to YAP. We chose to focus on COX2 and MMP7 for the current study because genetic deletion of either Ptgs2 (encoding Cox2) or Mmp7 delays PanIN progression in KC mice, and inhibitors targeting either human protein have undergone or are undergoing clinical trials for PDAC or other types of cancers (12, 13, 80) . First, we confirmed through IHC analysis of pancreata from KC, KYC, KPC, and KPYC mice that deletion of Yap also blocked the induction of Cox2 and Mmp7 abundance by oncogenic Kras in vivo (Fig. 5A) . Similar to the promoters of Ctgf and Cyr61, the promoters of Cox2 and Mmp7 contain multiple putative TEAD-binding sites. Chromatin immunoprecipitation (ChIP) assays confirmed that Yap bound to the promoter regions of Cox2 and Mmp7, but not the coding regions, which do not contain TEAD-binding motifs (Fig.  5B) . As expected, we also detected a specific association between Yap and the promoters of Ctgf and Cyr61 (fig. S8G) .
To further investigate how COX2 and MMP7 might contribute to YAPmediated regulation of pancreatic ductal cell proliferation, we treated KPY cells expressing either the Yap or vector control with marimastat (a clinical MMP inhibitor), Celebrex (a clinical COX2 inhibitor), or their combination. In Yap-reconstituted KPY cells, treatment with either inhibitor alone modestly reduced cell proliferation, whereas combined treatment significantly suppressed the proliferative rate of these cells to near that of control KPY cells (Fig. 5C ). In contrast, individual or combined treatment had no effect on the proliferation of Yap-deficient KPY cells that have minimal abundance of Cox2 and Mmp7 (Figs. 4, B and C, and 5C), indicating that the proliferative inhibition by marimastat and Celebrex in Yap-reconstituted KPY cells was unlikely to be due to off-target effects.
Ablation of Yap from Kras and Kras:Trp53 mutant pancreatic epithelial cells dampens their ability to elicit stromal response in vivo CTGF, CYR61, COX2, MMP7, IL-1a, and IL-6 are all implicated in various aspects of the stromal response that creates a tumor microenvironment that fuels PDAC progression (12, 14, 82, (88) (89) (90) (91) (92) (93) (94) (95) . In pancreata from KYC and KPYC mice, loss of Yap from pancreatic epithelial cells not only blocked epithelial cell proliferation but also led to a marked reduction in the number of Ki-67-positive stromal cells surrounding the ADM and early PanIN lesions (Fig. 3, A and B) . Thus, both autocrine and paracrine mechanisms likely contribute to the profound effects of Yap and the Yap-controlled secretome on PanIN cell proliferation and progression in vivo.
To understand how Yap modulates the tumor microenvironment by controlling the abundance of these secreted factors, we stained pancreatic tissue from 3-month-old and 7-week-old KC, KYC, KPC, and KPYC mice with markers for activated cancer-associated fibroblasts (CAFs), collagen, and infiltrating immune cells, which are main components of the desmoplastic stroma that encapsulate PanINs and PDAC (96). CAFs, a major cellular component and source of collagen in PDAC-associated stroma, express the myofibroblast marker a-SMA and the mesenchymal marker vimentin (97) . We found that a-SMA + :vimentin + CAFs accumulated around many of the neoplastic lesions in all of the KC, KYC, KPC, and KPYC pancreata examined, regardless of age (Fig. 6) . Nevertheless, we did notice a moderate decrease in the intensity and area of a-SMA and vimentin staining around ADM and early PanIN lesions from 7-week-old KPYC mice, which was accompanied by a significant reduction in collagen abundance (Fig. 6 ). These findings suggest that loss of YAP in KRAS-and TP53-mutant pancreatic epithelial cells compromises the recruitment and activation of stromal fibroblasts and, consequently, the production of collagen.
We used an antibody against CD45 (a lymphocyte marker) to detect the presence and localization of infiltrating immune cells in pancreata from KC, KYC, KPC, and KPYC mice. Whereas a large number of CD45 + lymphocytes were recruited to the stromal compartments in pancreata from 3-month-old KC and KPC mice, as previously reported (98), we found that CD45 + immune infiltrates were absent in KYC and KPYC pancreata of the same age or older (Fig. 6) . To determine whether the differences in CD45 staining in pancreata from adult KC, KYC, KPC, and KPYC mice was due to differences in disease progression, we performed IHC analysis for CD45 on , Il-6 (150 ng/ml), or Il-1a (10 ng/ml), singly or in combination as indicated. Data are means ± SD from three independent experiments. *P < 0.01, **P < 0.001, ***P < 0.0001, twotailed t test.
pancreatic sections from 7-week-old KPC and KPYC mice. We detected CD45 + lymphocytes in the vicinity of the ADM and early PanIN lesions from KPC, but not KPYC, mice (Fig. 6) . These results illustrate that YAP deficiency in pancreatic neoplastic epithelial cells impedes their ability to elicit a pro-tumor immune response that is critical for PDAC progression (96) .
Oncogenic KRAS induces posttranscriptional modification of YAP and augments its transcriptional activity through the MAPK pathway Deletion of Yap did not affect the activation of major oncogenic Kras effector pathways in the mouse pancreas ( Fig. 2A) , suggesting that YAP most likely acts more downstream in the oncogenic RAS signaling network. Therefore, we focused on examining how oncogenic RAS, its main effector pathways, and YAP coordinate in transcription regulation. First, we examined how expression of wild-type, constitutively active (G12V), or dominantnegative (S17N) Ras (either HRAS or KRAS, herein referred to as H/KRAS) affected YAP/TEAD-mediated transcription using a CTGF luciferase reporter containing TEAD-binding motifs in human embryonic kidney (HEK) 293T cells. H/KRAS WT and H/KRAS G12V , but not H/KRAS S17N , promoted the transcriptional activity of YAP (Fig. 7, A and B 127 to which 14-3-3 binds when phosphorylated by LATS1), or YAP 5SA (mutated at one or all five LATS1/2 phosphorylation sites, rendering it insensitive to regulation by the Hippo kinase cascade and thus constitutively localized to the nucleus) also synergistically stimulated CTGF and CYR61 transcript and protein abundance (Fig. 7, B to F) . Moreover, expression of HRAS G12V or MEK DD induced mobility shifts for YAP 5SA on SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and this effect and that on the abundance of CTGF and CYR61 protein were reversed by treatment with small interfering RNAs (siRNAs) targeting ERK1 and ERK2 (Fig. 7, F and G) . These results suggest that oncogenic RAS induces posttranscriptional modification of YAP through the MAPK pathway and augments its transcriptional activity. Consistent with oncogenic RAS acting independently of the Hippo pathway, we found that expression of HRAS G12V did not affect either the subcellular distribution of endogenous YAP or its phosphorylation at Ser 127 ( Fig. 7H) .
There are multiple conserved S/TP residues (the minimal ERK phosphorylation motif) within the YAP protein sequence. We mutated a number of these sites and found that only S367A mutation abolished oncogenic KRAS-induced YAP mobility shift ( fig. S9A ). However, mutation of S367A alone or in combination with several other putative ERK phosphorylation sites did not significantly alter the transcriptional activity of YAP in the presence or absence of oncogenic RAS ( fig. S9B ), suggesting that additional phosphorylation or other posttranscriptional events are necessary to modulate the transcriptional activity of YAP in response to oncogenic RAS and MAPK signaling. Finally, we found that the ability of KRAS G12V to induce YAP 5SA -mediated transcription was severely compromised in the TEAD-binding defective YAP 5SA/S94A mutant ( fig. S9C ) (99), implying the requirement of intact YAP/ TEAD transcriptional complexes in mediating oncogenic RAS-induced transcription program.
DISCUSSION
KRAS mutations are present in nearly all PDAC (4) . Point mutations of the TP53 tumor suppressor have also been described in about 75% of PDAC (7) . Here, we identified Yap as a critical partner to mutant Kras and Trp53 in driving PDAC oncogenesis in mice by acting as a critical transcriptional switch in multiple autocrine and paracrine Data are means ± SD from three independent experiments. *P < 0.01, **P < 0.001, ***P < 0.0001, two-tailed t test.
signaling loops required for sustaining not only the proliferation of KRASmutant neoplastic ductal cells but also the stromal response and PanIN progression to PDAC (Fig. 7I) . A number of genes, including EGFR, ADM17, PDK1, Gli1, and Sox9, are required for KRAS-induced ADM, commonly thought to be the initiating step in PDAC development (16) (17) (18) (19) (20) (21) (22) 100) . We found that Yap was dispensable for ADM in mice but was necessary for subsequent progression to late-stage PanINs and PDAC in both Kras and Kras:Trp53 mutant mice. The marked effect of Yap deletion on PanIN progression is also in contrast to those of Rac1, STAT3, Gli, IKK2, Il-6, Mmp7, and Cox2, which when knocked out singly in the same GEMMs delayed but did not prevent PDAC development (11-14, 17, 18, 101) . Thus, YAP may be the first molecule identified to be absolutely required for PanIN progression into PDAC.
Our data indicate that YAP acts as a critical transcriptional switch by promoting the expression of an oncogenic KRAS secretome that includes CTGF, CYR61, COX2 and PGE, MMP7, IL-6, and IL-1a. We also found that in culture, the YAP-controlled secretome can act in an autocrine fashion to promote the proliferation of KRAS mutant pancreatic ductal cells. Its in vivo roles are much more profound, observed as epithelial cell proliferation arrest, compromised immune response, and a blockade of PanIN progression resulting from Yap inactivation in Kras or Kras:Trp53 mutant pancreatic neoplastic epithelial cells in mice. Individual inactivation of these secreted factors genetically or pharmacologically only slowed the progression to PDAC in KC or KPC mice (13, 80, 81, 101) , whereas only when added in combination in culture did these factors effectively rescue the proliferation defect in Yapdeficient mouse pancreatic ductal cells. Thus, the prevention of PDAC development in mice by Yap deletion most probably reflected the cumulative effects of transcriptional blockade of these six-and perhaps additional-Yap target genes. Further studies will identify the minimum set of YAP targets required for sustaining neoplastic proliferation and PDAC progression in KRAS mutant pancreas. Although YAP is reportedly broadly expressed in the developing pancreas (72, 73) , Yap deletion had no apparent effect on pancreatic development, homeostasis, or function in mice. This is in contrast to the liver, in which Yap knockout impairs the development of bile ducts, the survival of hepatocytes, and normal organ function and fails to prevent oncogenic Kras-induced hepatocellular carcinoma (102) . Thus, there are clear tissue-specific differences in the function of YAP during development and tumorigenesis.
Notably, there may be a tissue-specific requirement of certain downstream effectors in mutant KRAS-induced oncogenesis. For example, deletion of Egfr prevents oncogenic Kras G12V -driven PDAC development but does not affect Kras G12V -driven lung and intestinal tumors in mice (19) . Similarly, abundance of phosphoinositide-dependent kinase 1 (PDK1) is rate-limiting for Kras G12D -driven PDAC, but not non-small cell lung carcinoma (NSCLC), formation (21) . On the other hand, deletion of Craf1, which encodes c-Raf, blocks Kras G12D -induced NSCLC but not PDAC development (21, 103, 104) . These findings underscore the complexity Fig. 6 . Deletion of Yap dampens the stromal response in Kras and Kras:Trp53 mutant pancreata. Representative images of IHC staining for a-SMA, vimentin, collagen, and CD45 on pancreatic sections from 3-monthold KC, KPC, KYC, and KPYC mice and 7-week-old KPC and KPYC mice. Yellow arrowheads, positively stained stroma; white arrowheads, negatively stained stroma; asterisks, blood vessels. Scale bar, 100 mm.
of oncogenic KRAS-induced carcinogenesis and the necessity for further studies to determine the role of YAP in other KRAS-induced cancer types.
Although we and others have shown that the overall mRNA and protein abundance of YAP is increased in human and mouse PDAC compared with normal pancreatic tissues (72, 73), we found robust cytoplasmic and nuclear localization of YAP in normal ductal and centroacinar cells similar to those in PanINs and PDACs, suggesting that, unlike other cancer types, the overall increase in YAP abundance in PDAC tumors likely reflects the shift in cell composition from a majority of acinar cells (which have low YAP abundance) in the normal pancreas to a majority of neoplastic ductal cells (which have high YAP abundance) in PDAC tumors.
Another interesting finding was that oncogenic KRAS signaled through the MAPK pathway to modulate the transcriptional activity of YAP (including mutant YAP S127A and YAP 5SA , which are uncoupled from Hippo pathway regulation), without affecting its subcellular localization. Indeed, pancreatic ductal cells (both normal and neoplastic) likely contain minimal Hippo activity, as indicated by the abundance of nuclear YAP in these cells. Our results suggest that oncogenic KRAS may bypass the Hippo pathway and potentiate or direct the transcriptional activity of YAP through phosphorylation or other forms of posttranscriptional modification mediated by ERK and its downstream targets (Fig. 7I) . Notably, the primary phosphorylation site causing the mobility shift for YAP in response to oncogenic RAS ( fig. S9A ), Ser 367 , is located within the transactivation domain (TA) of YAP. Oncogenic RAS and the MAPK pathway induce phosphorylation within the TA domain of several other transcription factors, leading to phosphorylation-specific recruitment of coactivators and enhanced transcription (105) (106) (107) . It is tempting to speculate that posttranscriptional modification of YAP at Ser 367 and additional sites may recruit coactivators that cooperate with YAP in promoting the transcription of KRAS and YAP co-regulated genes. Further studies will identify these putative YAP transcriptional partners and the specific mechanisms of their recruitment.
Because of the limitation of our GEMMs in which Yap was deleted concurrently with activation of mutant Kras and Trp53, our current study did not directly address whether YAP is required for tumor maintenance in established PDAC. Developing new transgenic mouse models that enable Yap deletion to be temporally separated from activation of mutant Kras and Trp53 are necessary to establish unequivocally the role of YAP in PDAC maintenance and progression. Nonetheless, we did uncover several lines of evidence supporting the continued requirement for YAP in established PDAC. First, we demonstrated that YAP is widely expressed in primary human PDAC. Second, we showed that YAP expression is necessary for maintaining the expression of the six noted secreted factors in KRAS mutant human and mouse PDAC lines. Last, we found that even a modest decrease in YAP expression was sufficient to inhibit the proliferation of the aforementioned PDAC lines.
As a transcriptional regulator with no enzymatic pocket, YAP poses substantial challenges as a drug target. Despite this, there has been some recent progress in developing small-molecule YAP inhibitors (108) (109) (110) (111) (112) . An alternative to directly targeting YAP to treat PDAC may be to combine a cocktail of inhibitors or therapeutic antibodies against multiple components of the KRAS/YAP secretome. Clinical trials have been conducted with COX2 and MMP7 inhibitors as single agents for PDAC, yielding mostly disappointing results (113) (114) (115) . A clinical trial is currently ongoing for a CTGF-targeted antibody in PDAC and other cancers (116) . Clinical agents targeting IL-6 and IL-1a are also available, although they have not been tested in PDAC (117) . We found that combination of COX2 and MMP7 inhibitors more efficiently inhibited the proliferation of Yap-positive pancreatic ductal cells than either inhibitor alone, suggesting that combination strategies with available agents may achieve optimum clinical outcome in PDAC without causing unmanageable toxicity. , and p48-Cre (102, (118) (119) (120) were interbred to generate all experimental cohorts (table S1). All animal experiments were conducted according to protocol #11-055 approved by the Institutional Animal Care and Use Committee at Georgetown University.
MATERIALS AND METHODS
Generation of mouse strains
Cell culture, transfection, and infection
The human pancreatic cancer cell line Colo-357 was cultured in RPMI 1640 (Sigma-Aldrich Corp.) supplemented with 10% fetal bovine serum (FBS). HEK293T, 293 Phoenix-A, and mouse pancreatic tumor cell line mPDAC-G9 were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 10% FBS. The primary mouse pancreatic cells were cultured in Waymouth's MB 752/1 (Sigma-Aldrich) supplemented with 10% FBS and soybean trypsin inhibitor (STI; 0.1 mg/ml; AMRESCO, LLC) on collagen-coated plates.
pLKO-shRNA lentiviral constructs targeting human and mouse Yap (TTRCN0000107266: 5′-TTCTTTATCTAGCTTGGTGGC-3′, TRCN0000107268: AAAGGATCTGAGCTATTGGTC, and TRCN0000095864: 5′-TTAACAAAGGAATCTGTCTGC-3′) were purchased from Thermo Scientific Open Biosystems. Lentiviral and retroviral productions were performed as previously described (121) .
Mouse acinar explant preparation and in vitro ADM assay
Mouse pancreatic explant cultures were established by modifying previously published protocols (122, 123) . Briefly, whole pancreata were harvested and digested in collagenase type 4 (4000 U/ml, Worthington Biochemical Corp.) for 50 min at 37°C. After multiple washes with Waymouth's MB 752/1 supplemented with 5% FBS, collagenase-digested pancreatic tissue was sequentially filtered through 90-µm metal mesh filters. The filtrate was then passed through a 30% FBS cushion by centrifugation for 5 min at 1000g. The cell pellet was resuspended in Waymouth's culture medium [Waymouth's MB 752/1 Medium supplemented with penicillin/streptomycin and STI (0.1 mg/ml)]. After incubation with adenoviruses carrying GFP or Cre-GFP (Gene Transfer Vector Core of University of Iowa) at 37°C for 1 hour, the cells were pelleted and resuspended in Waymouth's culture medium. An equal volume of neutralized rat-tail collagen type I (RTC) (BD Biosciences) mixture was added to the cellular suspension. The cellular/RTC suspension was pipetted into culture dish precoated with RTC. After solidification, Waymouth's culture medium was added. Cultures were maintained at 37°C in a 5% CO 2 humidified chamber for up to 3 days, then switched to Waymouth's culture medium supplemented with 10% FBS.
Cell proliferation and EdU incorporation assays
For cell proliferation assays, human or mouse pancreatic tumor cell lines were seeded in triplicate onto 12-well plates, trypsinized, and counted at the indicated times using Multisizer 3 Coulter Counter (Beckman Coulter Inc.). Colo-357 and mPDAC-G9 cells expressing control or Yap shRNAs were plated at 5 × 10 4 cells per well. Primary mouse pancreatic cells expressing pBABE vector or pBABE-Yap were plated at 2 × 10 4 cells per well. For treatment with secreted factors, recombinant human MMP7 (200 ng/ml, Millipore), murine Il-6 (150 ng/ml, Invitrogen), murine Il-1a (10 ng/ml, Sino Biological Inc.), and PGE 2 (10 mM, Enzo Life Sciences Inc.) were added singly or in combination to the medium, and cells were incubated for three additional days.
For EdU incorporation assays, freshly isolated pancreatic epithelial cells infected with Ad-GFP or Ad-Cre-GFP were plated onto collagen-coated coverslips in Waymouth's MB 752/1 Medium supplemented with penicillin G (1000 U/ml), streptomycin (100 mg/ml), STI (0.1 mg/ml), and 10% FBS. After 3 days in culture, EdU was added to the medium, and cells were incubated for an additional 14 hours. EdU-positive cells were detected using the Click-iT EdU Alexa Fluor 594 Imaging Kit according to the manufacturer's instructions (Invitrogen). Nuclei were counterstained with 4′,6-diamidino-2-phenylindole.
Glucose tolerance test
Three-month-old YC mice with age-matched wild-type littermates were subjected to fasting for 12 hours before the baseline blood glucose level was first measured for each mouse using OneTouch UItraMini Blood Glucose Monitoring System according to the manufacturer's instructions (LifeScan Inc.). Sterilized D-glucose (200 mg/ml) was then intraperitoneally injected into each mouse (2 mg/g in PBS), and blood glucose was measured again at 30, 60, and 120 min after the injection.
Acute pancreatitis induction
Two-month-old wild-type and YC mice were intraperitoneally injected seven times with caerulein (50 mg/kg) at 1-hour intervals. Mice were euthanized 48 hours after the first injection, and the entire pancreas was dissected and fixed in 10% formalin.
Quantitative real-time RT-PCR
Total mRNA was isolated using TRIzol reagent (Invitrogen). Reverse transcription was performed using iScript cDNA Synthesis Kit according to the manufacturer's instructions (Bio-Rad Laboratories Headquarters). The resulting complementary DNA (cDNA) products were amplified with iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories). All reactions were performed in triplicate. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (for human) or hypoxanthineguanine phosphoribosyltransferase (HPRT) (for mouse) was used for normalization. Relative gene expression was calculated as unit value of 2 −DCt = 2 −[Ct (GAPDH or HPRT) − Ct (gene of interest)] , where C t is the threshold cycle value defined as the fractional cycle number at which the target fluorescent signal passes a fixed threshold above baseline. The sequences of the primers used in the study are listed in table S3.
Chromatin immunoprecipitation
ChIP analysis was performed as previously described using normal rabbit IgG (Santa Cruz Biotechnology, sc-2027X) and antibodies against Yap (Santa Cruz Biotechnology, sc-15407X) and Pol II (Santa Cruz Biotechnology, sc-899X) (121) . Precipitated DNA was eluted and amplified using qRT-PCR with primer pairs flanking different regions of the mouse Cyr61, Ctgf, Cox2, and Mmp7 promoters that contain putative TEADbinding sites. The primer sequences used in the study are listed in table S4.
Western blot, IHC, and immunofluorescence
Western blot analysis was performed as previously described (124) . Human pancreatic TMAs (#PA1001 and #PA207) were purchased from US Biomax Inc. Mouse pancreas was fixed in 10% buffered formalin and embedded in paraffin. For IHC, unstained pancreatic slides were deparaffinized and heated in standard citrate or tris-EDTA retrieval buffer for 30 min at 95°C. After incubation overnight with the primary antibodies at 4°C, the slides were incubated with biotinylated secondary antibodies (Vector Laboratories Ltd.) for 1 hour at room temperature. Antibody labeling was visualized using the VECTASTAIN ABC kit (Vector Laboratories Ltd.) followed by staining with 3,3′-diaminobenzidine tetrahydrochloride plus (DAB+) according to the manufacturer's instructions (Thermo Scientific) or using the Vector Blue Alkaline Phosphatase Substrate Kit (Vector Laboratories Ltd.). The antibodies used for Western blot and IHC analyses are listed in table S5. Collagen staining was performed using the Masson Trichrome Stain Kit according to the manufacturer's instructions (Sigma).
Subcellular fractionation
For subcellular fractionation experiments, the cytoplasmic fraction was extracted with hypotonic buffer [10 mM Hepes (pH 7.9), 1.5 mM MgCl 2 , 10 mM KCl, and 0.5 mM fresh dithiothreitol], and pellets containing nuclei were washed twice with hypotonic buffer and subsequently lysed in radioimmunoprecipitation assay buffer.
Luciferase reporter assay
The CTGF luciferase reporter was a gift from K. Lyons [University of California, Los Angeles (UCLA)] (125). Renilla luciferase vector was purchased from Promega. Luciferase reporter activities were determined with the Dual Luciferase Assay Kit (Promega). The reporter's firefly luciferase activity was normalized to that of the internal control Renilla luciferase before statistical analysis. The annotated relative luciferase activity is the ratio between firefly and Renilla luciferase activities.
Microarray data mining and statistical analysis
Gene Expression Omnibus data sets GSE15471, GSE18670, GSE19650, and GSE16515 containing either normal pancreatic tissue or PDAC tumor cDNA samples hybridized to Human Genome U133 Plus 2.0 GeneChips were included in our analysis. Array data were normalized, and samples having an SE greater than 1.1 were excluded. GC-RMAwas used for probe-level normalization of array intensities (126) . Batch effects caused by multiple data sources were corrected using ComBat (127) . Probes from each probe set with the greatest interquartile range were retained for gene expression analysis. The Linear Models for Microarray (LIMMA) package was used for expression calculations (128) . Bonferroni-corrected Student's t tests were used to calculate P values. All analyses were done in the R programming and language software environment using packages available through Bioconductor (129) .
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